Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710925 | 0.89 | NR4A2 (0.40) | NR4A2HCAR2IDO1DHODHABCG2 | |
| SCHEMBL6794325 | 0.83 | HCAR2 (0.40) | HCAR2IDO1DHODHABCG2CDK8 | |
| SCHEMBL15346406 | 0.82 | HCAR2 (0.46) | HCAR2DHODHABCG2MAPT | |
| SCHEMBL6711937 | 0.81 | HCAR2 (0.41) | NR4A2HCAR2IDO1ABCG2 | |
| SCHEMBL6710746 | 0.80 | IDO1 (0.42) | NR4A2HCAR2IDO1DHODHABCG2 | |
| SCHEMBL6713591 | 0.73 | HCAR2 (0.40) | HCAR2IDO1DHODHABCG2 | |
| SCHEMBL6527179 | 0.69 | IDO1 (0.45) | NR4A2HCAR2IDO1ABCG2MAPK1 | |
| SCHEMBL6524942 | 0.69 | IDO1 (0.45) | NR4A2HCAR2IDO1ABCG2MAPK1 | |
| SCHEMBL9822370 | 0.68 | CYP3A4 (0.63) | NR4A2CDK8MAPK1MAPT | |
| SCHEMBL5390307 | 0.68 | ACHE (0.42) | NR4A2NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825210-B2 | 5,10-DIHYDROBENZO(B)(1,8)NAPHTHYRIDINE COMPOUNDS, N-OXIDES; 3,7-DICHLORO-5-ISOPROPOXYMETHYL-5-TRIFLUOROMETHYL-5,10 -DIHYDROBENZO(B)(1,8)NAPHTHYRIDINE FOR EXAMPLE; COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | JOHNSON BARRY L (US) | 2004-01-01 | — | — | US | disclosed |
| US-6593337-B1 | pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
| US-20020177603-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177603-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | POLRMT, TYMP, POLM | NR4A2 3318/4885HCAR2 3735/4885IDO1 1386/4885 |
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | POLRMT, TYMP, POLM | NR4A2 3318/4885HCAR2 3735/4885IDO1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.